Sign up to save your podcasts
Or
Share A New Light in Higher-Risk MDS: Emerging Treatment Options
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
A New Light in Higher-Risk MDS: Emerging Treatment Options
CME credits: 0.25
Valid until: 08-04-2023
Claim your CME credit at https://reachmd.com/programs/cme/a-new-light-in-higher-risk-mds-emerging-treatment-options/13517/
New and novel therapeutics for the treatment myelodysplastic syndrome (MDS) are in development. What are these agents, and how do they work? Listen in as Dr. Andrew Brunner and Dr. Amy DeZern discuss ongoing clinical trials, current data from those trials, and the future potential for tailoring treatment plans.
Since the completion of this activity, the U.S. Food and Drug Administration has lifted the partial clinical hold placed on studies evaluating the investigational agent magrolimab in combination with azacytidine for the treatment of MDS and AML.
https://clinicaltrials.gov/ct2/results?cond=&term=Magrolimab+&cntry=&state=&city=&dist=
=
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.25
Valid until: 08-04-2023
Claim your CME credit at https://reachmd.com/programs/cme/a-new-light-in-higher-risk-mds-emerging-treatment-options/13517/
New and novel therapeutics for the treatment myelodysplastic syndrome (MDS) are in development. What are these agents, and how do they work? Listen in as Dr. Andrew Brunner and Dr. Amy DeZern discuss ongoing clinical trials, current data from those trials, and the future potential for tailoring treatment plans.
Since the completion of this activity, the U.S. Food and Drug Administration has lifted the partial clinical hold placed on studies evaluating the investigational agent magrolimab in combination with azacytidine for the treatment of MDS and AML.
https://clinicaltrials.gov/ct2/results?cond=&term=Magrolimab+&cntry=&state=&city=&dist=
=